サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1532131

分子診断の世界市場の評価：製品・サービス別、検査タイプ別、サンプルタイプ別、技術別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Molecular Diagnostics Market Assessment, By Product and Service, By Test Type, By Sample Type, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日
ページ情報
英文 230 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
分子診断の世界市場の評価：製品・サービス別、検査タイプ別、サンプルタイプ別、技術別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
出版日: 2024年08月13日
発行: Markets & Data
ページ情報: 英文 230 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の分子診断の市場規模は、2023年の143億1,000万米ドルから2031年に308億3,000万米ドルに達すると予測され、2024年～2031年の予測期間にCAGRで10.07%の成長が見込まれます。

分子診断は、重要な情報を提供することで、患者や医療従事者が治療について十分な知識を持った判断を下し、良好な結果を導くのに役立ちます。分子診断技術は、高感度で迅速な検出方法を可能にするため、臨床現場で有用であることが示されており、がんやその他の慢性疾患を含むさまざまな感染性疾患のモニタリングが容易になります。疾病の増加、病原体の増加、さらには疾病に罹患しやすく継続的な診断が必要な老年人口の増加により、分子診断市場の拡大が見込まれています。遺伝学的検査、微生物、性病、腫瘍、血液スクリーニング、ウイルス、組織型、出生前診断など、分子診断の普及により数多くの医学疾患が効果的に特定されています。DNA、RNA、タンパク質の研究を利用した実験室ベースの分子診断は、ヒトの疾患の検出に使用される重要な器具です。分子診断キットや試薬は、目的の用途に応じて調整され、特定の細菌、ウイルス、寄生虫の配列に特異的なプローブを含んでいます。分子診断市場は、あらゆる種類の投薬や治療を開始する前に不可欠な、バイオマーカーに特化した検査キットの使用が増加していることから、拡大が見込まれています。例えばUSFDAは、2023年5月にHologic, Inc.のPanther Fusion SARS-CoV-2/Flu A/B/RSVアッセイの510（k）認可を与えました。このアッセイは、分子診断検査によってもっとも流行している4種類の呼吸器ウイルスを区別します。

慢性疾患の有病率の増加による市場成長

分子診断市場は、慢性疾患の罹患率の増加によって大きく拡大しています。高齢化、ライフスタイルの変化、環境要因などはいずれも、がん、糖尿病、心血管疾患などの慢性疾患の増加に寄与しています。これらの疾患を管理し、効果的に治療するには、先進の診断法が必要です。このような状況では、遺伝子、ゲノム、プロテオミクスデータを解析する先進技術を用いた分子診断が不可欠です。慢性疾患に関連する特定のバイオマーカーや遺伝子変化を同定することで、疾患のタイムリーで正確な発見が容易になります。各患者固有の分子プロファイルに従って治療レジメンをカスタマイズすることは、治療効果を高め、患者の転帰を向上させます。例えば、腫瘍に特有の変異を検出することで、分子診断は、薬剤を選択する際の試行錯誤の必要性を最小限にすることで、最適ながん治療法を決定する手助けをする可能性があります。このような診断により、疾患の進行や治療に対する身体の反応を追跡し続けることが容易になり、迅速な治療法の変更が可能になります。

慢性疾患の有病率が伸び続けていることから、疾病の原因や患者の健康状態についての包括的かつ個別化された知見を提供する分子診断に対するニーズは高まっています。このような動向は、分子診断産業における継続的な開発と技術革新を促進し、長期的な疾患治療の改善に寄与しています。例えば、International Diabetes Federationは2023年に、2型糖尿病の有病率が世界中で顕著に増加していると報告しています。同連盟の調査によると、2023年に世界で5億3,700万人の成人が糖尿病を患っており、前年より大幅に増加しています。高齢化、肥満率の増加、座りがちな生活習慣がこの動向の原因とされています。2型糖尿病患者の増加は、この長期的な疾患の影響を制御し軽減するための、よりよい予防策と医学的治療へのニーズを浮き彫りにしています。

技術開発が市場成長を促進

技術開発が分子診断市場の拡大において大きな役割を果たしています。この分野はハイスループットシーケンシング、リアルタイムPCR、次世代シーケンシング（NGS）技術の進歩により革命的な変化を遂げ、精度、スピード、包括的な診断能力が向上しました。これらの技術により、以前には考えられなかったような精度で遺伝物質を解析することが可能になり、疾患の早期発見や個別化治療に役立っています。

当レポートでは、世界の分子診断市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の分子診断市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
    • 数量
  • 市場シェア分析と予測
    • 製品・サービス別
    • 検査タイプ別
    • サンプルタイプ別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 地域別
    • 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
  • 市場マップ分析（2023年）
    • 製品・サービス別
    • 検査タイプ別
    • サンプルタイプ別
    • 技術別
    • 用途別
    • エンドユーザー別
    • 地域別

第5章 北米の分子診断市場の見通し（2017年～2031年）

  • 市場規模の分析と予測
    • 金額
    • 数量
  • 市場シェア分析と予測
    • 製品・サービス別
    • 検査タイプ別
    • サンプルタイプ別
    • 技術別
    • 用途別
    • エンドユーザー別
    • シェア：国別
  • 市場の評価：国別
    • 米国の分子診断市場の見通し（2017年～2031年）
    • カナダ
    • メキシコ

第6章 欧州の分子診断市場の見通し（2017年～2031年）

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • ポーランド

第7章 アジア太平洋の分子診断市場の見通し（2017年～2031年）

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第8章 南米の分子診断市場の見通し（2017年～2031年）

  • ブラジル
  • アルゼンチン

第9章 中東・アフリカの分子診断市場の見通し（2017年～2031年）

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ
  • イスラエル

第10章 需給分析

第11章 輸入と輸出の分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場促進要因
  • 市場の課題

第17章 市場の動向と発展

第18章 規制枠組みとイノベーション

  • 臨床試験
  • 規制当局の承認

第19章 特許情勢

第20章 ケーススタディ

第21章 競合情勢

  • マーケットリーダー上位5社の競合マトリクス
  • 上位5社のSWOT分析
  • 主要企業上位10社の情勢
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd
    • Hologic, Inc.
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • bioMerieux SA
    • Illumina, Inc.
    • QIAGEN N.V.
    • Myriad Genetics, Inc.
    • Siemens Healthineers

第22章 戦略的推奨

第23章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 4. Global Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 5. Global Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 6. Global Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 7. Global Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 8. Global Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 9. Global Molecular Diagnostics Market Share (%), By Region, 2017-2031F
  • Figure 10. North America Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 11. North America Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 12. North America Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 13. North America Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 14. North America Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 15. North America Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 16. North America Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 17. North America Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 18. North America Molecular Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 19. United States Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. United States Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 21. United States Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 22. United States Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 23. United States Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 24. United States Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 25. United States Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 26. United States Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 27. Canada Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Canada Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Canada Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 30. Canada Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 31. Canada Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 32. Canada Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 33. Canada Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 34. Canada Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 35. Mexico Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 36. Mexico Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 37. Mexico Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 38. Mexico Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 39. Mexico Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 40. Mexico Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 41. Mexico Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 42. Mexico Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 43. Europe Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 44. Europe Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 45. Europe Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 46. Europe Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 47. Europe Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 48. Europe Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 49. Europe Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 50. Europe Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 51. Europe Molecular Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 52. Germany Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Germany Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Germany Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 55. Germany Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 56. Germany Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 57. Germany Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 58. Germany Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 59. Germany Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 60. France Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. France Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. France Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 63. France Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 64. France Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 65. France Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 66. France Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 67. France Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 68. Italy Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 69. Italy Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 70. Italy Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 71. Italy Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 72. Italy Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 73. Italy Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 74. Italy Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 75. Italy Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 76. United Kingdom Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. United Kingdom Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. United Kingdom Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 79. United Kingdom Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 80. United Kingdom Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 81. United Kingdom Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 82. United Kingdom Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 83. United Kingdom Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 84. Russia Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 85. Russia Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 86. Russia Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 87. Russia Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 88. Russia Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 89. Russia Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 90. Russia Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 91.
  • Figure 92. Russia Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 93. Netherlands Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 94. Netherlands Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 95. Netherlands Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 96. Netherlands Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 97. Netherlands Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 98. Netherlands Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 99. Netherlands Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 100. Netherlands Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 101. Spain Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Spain Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Spain Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 104. Spain Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 105. Spain Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 106. Spain Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 107. Spain Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 108. Spain Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 109. Turkey Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. Turkey Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. Turkey Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 112. Turkey Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 113. Turkey Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 114. Turkey Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 115. Turkey Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 116. Turkey Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 117. Poland Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Poland Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Poland Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 120. Poland Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 121. Poland Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 122. Poland Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 123. Poland Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 124. Poland Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 125. South America Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 126. South America Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 127. South America Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 128. South America Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 129. South America Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 130. South America Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 131. South America Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 132. South America Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 133. South America Molecular Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 134. Brazil Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 135. Brazil Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 136. Brazil Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 137. Brazil Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 138. Brazil Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 139. Brazil Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 140. Brazil Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 141. Brazil Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 142. Argentina Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 143. Argentina Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 144. Argentina Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 145. Argentina Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 146. Argentina Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 147. Argentina Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 148. Argentina Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 149. Argentina Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 150. Asia-Pacific Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. Asia-Pacific Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. Asia-Pacific Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 153. Asia-Pacific Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 154. Asia-Pacific Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 155. Asia-Pacific Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 156. Asia-Pacific Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 157. Asia-Pacific Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 158. Asia-Pacific Molecular Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 159. India Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 160. India Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 161. India Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 162. India Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 163. India Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 164. India Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 165. India Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 166. India Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 167. China Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. China Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. China Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 170. China Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 171. China Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 172. China Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 173. China Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 174. China Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 175. Japan Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Japan Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Japan Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 178. Japan Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 179. Japan Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 180. Japan Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 181. Japan Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 182. Japan Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 183. Australia Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 184. Australia Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 185. Australia Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 186. Australia Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 187. Australia Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 188. Australia Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 189. Australia Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 190. Australia Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 191. Vietnam Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 192. Vietnam Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 193. Vietnam Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 194. Vietnam Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 195. Vietnam Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 196. Vietnam Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 197. Vietnam Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 198. Vietnam Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 199. South Korea Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 200. South Korea Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 201. South Korea Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 202. South Korea Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 203. South Korea Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 204. South Korea Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 205. South Korea Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 206. South Korea Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 207. Indonesia Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 208. Indonesia Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 209. Indonesia Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 210. Indonesia Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 211. Indonesia Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 212. Indonesia Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 213. Indonesia Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 214. Indonesia Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 215. Philippines Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 216. Philippines Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 217. Philippines Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 218. Philippines Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 219. Philippines Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 220. Philippines Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 221. Philippines Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 222. Philippines Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 223. Middle East & Africa Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 224. Middle East & Africa Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 225. Middle East & Africa Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 226. Middle East & Africa Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 227. Middle East & Africa Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 228. Middle East & Africa Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 229. Middle East & Africa Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 230. Middle East & Africa Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 231. Middle East & Africa Molecular Diagnostics Market Share (%), By Country, 2017-2031F
  • Figure 232. Saudi Arabia Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 233. Saudi Arabia Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 234. Saudi Arabia Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 235. Saudi Arabia Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 236. Saudi Arabia Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 237. Saudi Arabia Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 238. Saudi Arabia Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 239. Saudi Arabia Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 240. UAE Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 241. UAE Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 242. UAE Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 243. UAE Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 244. UAE Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 245. UAE Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 246. UAE Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 247. UAE Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 248. South Africa Molecular Diagnostics Market, By Value, In USD Billion, 2017-2031F
  • Figure 249. South Africa Molecular Diagnostics Market, By Volume, In Million Units, 2017-2031F
  • Figure 250. South Africa Molecular Diagnostics Market Share (%), By Product and Service, 2017-2031F
  • Figure 251. South Africa Molecular Diagnostics Market Share (%), By Test Type, 2017-2031F
  • Figure 252. South Africa Molecular Diagnostics Market Share (%), By Sample Type, 2017-2031F
  • Figure 253. South Africa Molecular Diagnostics Market Share (%), By Technology, 2017-2031F
  • Figure 254. South Africa Molecular Diagnostics Market Share (%), By Application, 2017-2031F
  • Figure 255. South Africa Molecular Diagnostics Market Share (%), By End-user, 2017-2031F
  • Figure 256. By Product and Service Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 257. By Test Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 258. By Sample Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 259. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 260. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 261. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 262. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX11746

Global molecular diagnostics market is projected to witness a CAGR of 10.07% during the forecast period 2024-2031, growing from USD 14.31 billion in 2023 to USD 30.83 billion in 2031.

Molecular diagnostics help patients and healthcare professionals make educated decisions about their treatment, which leads to positive results, by offering vital information. Molecular diagnostics techniques have shown to be useful in clinical settings since they allow sensitive and quick detection methods, which makes it easier to monitor a variety of infectious disorders, including cancer and other chronic illnesses. The market for molecular diagnostics is expected to rise due to the growing illness, rising numbers of pathogens and even rising geriatric population, which is more prone to disease and hence needs continuous diagnosis. Numerous medical diseases have been effectively identified by the widespread use of molecular diagnostics, including genetic testing, microbiology, STDs, oncology, blood screening, virology, tissue type, and prenatal diagnosis. Using the study of DNA, RNA, or proteins, laboratory-based molecular diagnostics are vital instruments used for the detection of human diseases. Molecular diagnostic kits and reagents are tailored according to the desired use and contain probes that are unique to certain bacterial, viral, or parasitic sequences. The market for molecular diagnostics is expected to rise due to the growing use of biomarker-specific testing kits, which are essential before starting any kind of medication or treatment. The USFDA, for instance, granted 510(k) clearance for Hologic, Inc.'s Panther Fusion SARS-CoV-2/Flu A/B/RSV assay in May 2023. This assay distinguishes between the four most prevalent respiratory viruses by molecular diagnostic testing.

Market Growth Due to Rising Prevalence of Chronic Ailments

The market for molecular diagnostics is expanding significantly due to the increased incidence of chronic illnesses. Aging populations, changing lifestyles, and environmental factors are all contributing to the rise in chronic diseases such as cancer, diabetes, and cardiovascular ailments. For these illnesses to be managed and treated effectively, sophisticated diagnostic methods are required. In this setting, molecular diagnostics, which use advanced technology to analyze genetic, genomic, and proteomic data, are essential. Through the identification of particular biomarkers and genetic alterations linked to chronic disorders, they facilitate the timely and accurate detection of diseases. Customizing therapy regimens according to each patient's unique molecular profile increases treatment effectiveness and boosts patient outcomes. For instance, by detecting mutations unique to a tumor, molecular diagnostics might assist in determining the best cancer treatments by minimizing the need for trial-and-error when choosing medications. These diagnostics make it easier to continue tracking how the disease progresses and how the body responds to treatment, which enables prompt therapeutic modifications.

The need for molecular diagnostics that offer comprehensive and individualized insights into disease causes and patient health is growing as the prevalence of chronic diseases keeps rising. The pattern promotes ongoing development and innovation in the molecular diagnostics industry, aiding in the improved treatment of long-term medical disorders. For instance, the International Diabetes Federation reported in 2023 that there has been a notable global increase in prevalence of Type 2 diabetes. According to the federation's research, 537 million adults worldwide had diabetes in 2023, i.e., a significant increase over the previous year. Ageing populations, an increase in obesity rates, and sedentary lifestyles are blamed for the trend. The increasing number of people with Type 2 diabetes highlights the critical need for better preventative measures and medical therapies to control and lessen the effects of this long-term illness.

Technological Developments Fuel Market Growth

Technological developments have a major role in propelling the molecular diagnostics market's expansion. The area has seen a revolutionary change due to the advancement of high-throughput sequencing, real-time PCR, and next-generation sequencing (NGS) technologies, which offer enhanced precision, speed, and comprehensive diagnostic capabilities. These technologies make it possible to analyze genetic material with previously unheard-of precision, which helps with disease early detection and individualized therapy. High-throughput sequencing makes it possible to analyze multiple genetic variants which improves the efficiency of identifying mutations linked to disease. To diagnose infections and genetic abnormalities, real-time PCR improves the sensitivity and specificity of detecting particular genetic sequences. Deep genetic data insights are provided by NGS, which helps with focused therapy development and the identification of new biomarkers. Moreover, developments in data analytics and bioinformatics have enhanced the ability to comprehend intricate molecular data, enabling the extraction of useful insights from sizable datasets. Molecular diagnostics benefits from the integration of artificial intelligence (AI) and machine learning, which improves predictive analytics facilitates early diagnosis and personalized medication. The market for molecular diagnostics is growing due to these technical advancements since they provide more advanced instruments for accurate and effective illness detection and treatment. For instance, F. Hoffmann-La Roche Ltd. introduced the LightCycler PRO System in November 2023 to improve the usefulness of molecular PCR testing for applications such as in vitro diagnostics and translational research.

Instruments to Dominate the Global Molecular Diagnostics Market Share

Due to the high cost of equipment and the requirement for regular replacement or updates, the instruments category holds the highest revenue share of the market based on products and services. The rising incidence of chronic illnesses including cancer, genetic abnormalities, and infectious diseases, which need more sophisticated diagnostic techniques, expected to drive the demand for molecular diagnostic tools. This expansion can be linked to the growing need for personalized medicine and companion diagnostics, which need specifically designed instruments for particular uses. New and affordable diagnostic assays are anticipated to drive growth in the reagent and kit market. As more people are using electronic health record (EHR) and laboratory information management system (LIMS) systems, the software market is predicted to grow significantly over the course of the forecast period. More accurate and efficient patient diagnosis and treatment are expected to be made possible by the integration of molecular diagnostic software with electronic medical records.

Furthermore, it is anticipated that the advancement of machine learning and artificial intelligence (AI) technologies would support the growth of molecular diagnostic software by enabling the automated analysis of big datasets. For instance, Thermo Fisher Scientific, Inc. announced the release of a new digital PCR research tool called QuantStudio, Applied Biosystems, Absolute Q AutoRun dPCR (digital polymerase chain reaction) Suite in February 2023. Additionally, in May 2023, Sansure Biotech Inc. showcased its extensive line of IVD devices at EuroMedLab Rome 2023, which included the iconic III portable molecular workstations.

North America Dominates the Global Molecular Diagnostics Market Share

With the highest market share, North America led the largest proportion of the market. This is ascribed to the increasing prevalence of both infectious and chronic illnesses, which in turn motivates businesses to launch cutting-edge molecular diagnostic tests and propel market expansion. The growth is due to the robust healthcare infrastructure present in the region. Highly advanced diagnostic centers and laboratories in the region aid scientific development and growth, leading to a highly competitive market. For instance, QIAGEN N.V.'s therascreen PDGFRA RGQ PCR kit was approved by the USFDA in August 2023. This tool helps doctors detect individuals who have gastrointestinal stromal tumors (GIST). Additionally, the VIASURE Monkeypox viral Real-Time PCR Reagents, created by Becton, Dickinson and Company and CerTest Biotec, S.L. for Mpox viral identification, was authorized by the USFDA in January 2023. Furthermore, a strong healthcare system, excellent living standards, and consumer knowledge of early diagnosis serve as important growth-promoting factors.

Future Market Scenario (2024 - 2031F)

The main factors contributing to the anticipated growth of the molecular diagnostics market are the rising numbers of pathogens, the increasing prevalence of diseases, and, thus, the rising requirement to conduct diagnostic tests. However, the growing need to have precision medicine to maintain a healthy population is going to fuel market growth in the future. Players in this market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. Policies by welfare bodies and the government are greatly fueling the market expansion. For instance, the USFDA gave the COVID-19 and Flu Home Test, the first and only Emergency Use Authorization (EUA) for OTC usage at home and other non-laboratory locations.

Key Players Landscape and Outlook

Several companies are expanding their businesses by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launch of newly developed molecular diagnostics to help researchers and strengthen their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments, and partnerships are a few ways through which they are trying to achieve the same.

For example, in October 2023, QIAGEN N.V. and Myriad Genetics, Inc. collaborated to create companion diagnostic tests for cancer based on PCR, dPCR, and NGS technology.

Additionally, Oxford Nanopore and bioMerieux SA established a strategic alliance in April 2023 to use nanopore technology to provide innovative cures for infectious diseases.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Molecular Diagnostics Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Product and Service
      • 4.2.1.1. Reagents and Kits
      • 4.2.1.2. Instruments
      • 4.2.1.3. Services and Software
    • 4.2.2. By Test Type
      • 4.2.2.1. Lab Tests
      • 4.2.2.2. POC Tests
    • 4.2.3. By Sample Type
      • 4.2.3.1. Blood, Serum, and Plasma
      • 4.2.3.2. Urine
      • 4.2.3.3. Others
    • 4.2.4. By Technology
      • 4.2.4.1. Polymerase Chain Reaction (PCR)
      • 4.2.4.2. Isothermal Nucleic Acid Amplification Technology
      • 4.2.4.3. In-situ Hybridization
      • 4.2.4.4. DNA Sequencing
      • 4.2.4.5. Microarray
      • 4.2.4.6. Others
    • 4.2.5. By Application
      • 4.2.5.1. Infectious Diseases Tests
      • 4.2.5.2. Oncology Tests
      • 4.2.5.3. Genetic Tests
      • 4.2.5.4. Others
    • 4.2.6. By End-user
      • 4.2.6.1. Hospitals and Clinics
      • 4.2.6.2. Diagnostic Laboratories
      • 4.2.6.3. Others
    • 4.2.7. By Region
      • 4.2.7.1. North America
      • 4.2.7.2. Europe
      • 4.2.7.3. Asia-Pacific
      • 4.2.7.4. South America
      • 4.2.7.5. Middle East and Africa
    • 4.2.8. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Product and Service
    • 4.3.2. By Test Type
    • 4.3.3. By Sample Type
    • 4.3.4. By Technology
    • 4.3.5. By Application
    • 4.3.6. By End-user
    • 4.3.7. By Region

5. North America Molecular Diagnostics Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product and Service
      • 5.2.1.1. Reagents and Kits
      • 5.2.1.2. Instruments
      • 5.2.1.3. Services and Software
    • 5.2.2. By Test Type
      • 5.2.2.1. Lab Tests
      • 5.2.2.2. POC Tests
    • 5.2.3. By Sample Type
      • 5.2.3.1. Blood, Serum, and Plasma
      • 5.2.3.2. Urine
      • 5.2.3.3. Others
    • 5.2.4. By Technology
      • 5.2.4.1. Polymerase Chain Reaction (PCR)
      • 5.2.4.2. Isothermal Nucleic Acid Amplification Technology
      • 5.2.4.3. In-situ Hybridization
      • 5.2.4.4. DNA Sequencing
      • 5.2.4.5. Microarray
      • 5.2.4.6. Others
    • 5.2.5. By Application
      • 5.2.5.1. Infectious Diseases Tests
      • 5.2.5.2. Oncology Tests
      • 5.2.5.3. Genetic Tests
      • 5.2.5.4. Others
    • 5.2.6. By End-user
      • 5.2.6.1. Hospitals and Clinics
      • 5.2.6.2. Diagnostic Laboratories
      • 5.2.6.3. Others
    • 5.2.7. By Country Share
      • 5.2.7.1. United States
      • 5.2.7.2. Canada
      • 5.2.7.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Molecular Diagnostics Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
        • 5.3.1.1.2. By Volume
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Product and Service
          • 5.3.1.2.1.1. Reagents and Kits
          • 5.3.1.2.1.2. Instruments
          • 5.3.1.2.1.3. Services and Software
        • 5.3.1.2.2. By Test Type
          • 5.3.1.2.2.1. Lab Tests
          • 5.3.1.2.2.2. POC Tests
        • 5.3.1.2.3. By Sample Type
          • 5.3.1.2.3.1. Blood, Serum, and Plasma
          • 5.3.1.2.3.2. Urine
          • 5.3.1.2.3.3. Others
        • 5.3.1.2.4. By Technology
          • 5.3.1.2.4.1. Polymerase Chain Reaction (PCR)
          • 5.3.1.2.4.2. Isothermal Nucleic Acid Amplification Technology
          • 5.3.1.2.4.3. In-situ Hybridization
          • 5.3.1.2.4.4. DNA Sequencing
          • 5.3.1.2.4.5. Microarray
          • 5.3.1.2.4.6. Others
        • 5.3.1.2.5. By Application
          • 5.3.1.2.5.1. Infectious Diseases Tests
          • 5.3.1.2.5.2. Oncology Tests
          • 5.3.1.2.5.3. Genetic Tests
          • 5.3.1.2.5.4. Others
        • 5.3.1.2.6. By End-user
          • 5.3.1.2.6.1. Hospitals and Clinics
          • 5.3.1.2.6.2. Diagnostic Laboratories
          • 5.3.1.2.6.3. Others
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Molecular Diagnostics Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Molecular Diagnostics Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Molecular Diagnostics Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Molecular Diagnostics Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Danaher Corporation
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. F. Hoffmann-La Roche Ltd
    • 21.3.3. Hologic, Inc.
    • 21.3.4. Thermo Fisher Scientific Inc.
    • 21.3.5. Abbott Laboratories
    • 21.3.6. bioMerieux SA
    • 21.3.7. Illumina, Inc.
    • 21.3.8. QIAGEN N.V.
    • 21.3.9. Myriad Genetics, Inc.
    • 21.3.10. Siemens Healthineers

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer